688373.SHG Shanghai MicuRx Pharmaceutical Co. Ltd. A
- Market cap
- CNY 3.20B
- P/E
- -
- P/B
- 19.21x
- ROE
- -46.1%
- Dividend yield
- 0.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688373.SHG undervalued?
Graham numberThe Graham number of Shanghai MicuRx Pharmaceutical Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai MicuRx Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai MicuRx Pharmaceutical Co. Ltd. A yet.
Shanghai MicuRx Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai MicuRx Pharmaceutical Co. Ltd. A
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacter…
Full company profileShanghai MicuRx Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai MicuRx Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 7.66M | 48.2M | 90.8M | 130M | 142M | 179M |
| Gross Profit | - | 7.08M | 39.4M | 74.1M | 108M | 120M | 155M |
| Operating Income | -95.2M | -263M | -232M | -436M | -437M | -244M | -75.9M |
| EBITDA | - | - | -196M | -390M | -409M | -218M | -68.0M |
| Net Income | -86.3M | -226M | -220M | -421M | -441M | -242M | -75.1M |
| EPS | -0.16 | -0.43 | -0.34 | -0.64 | -0.67 | -0.37 | -0.11 |
| Balance Sheet | |||||||
| Total Assets | 675M | 649M | 1.50B | 1.17B | 849M | 705M | 628M |
| Total Liabilities | 55.2M | 210M | 283M | 335M | 410M | 500M | 465M |
| Shareholders' Equity | 620M | 438M | 1.21B | 834M | 439M | 206M | 163M |
| Cash & Short-term Investments | 227M | 146M | 151M | 166M | 386M | 316M | 282M |
| Cash Flow | |||||||
| Operating Cash Flow | -89.3M | -181M | -240M | -329M | -447M | -210M | - |
| Capital Expenditure | 800K | 22.9M | 12.2M | 7.66M | 915K | 549K | 183K |
| Free Cash Flow | -90.1M | -204M | -252M | -337M | -448M | -211M | -53.0M |
| Ratios | |||||||
| ROE | -13.9% | -51.6% | -18.1% | -50.5% | -100.4% | -117.6% | -46.1% |
| ROA | -12.8% | -34.9% | -14.7% | -36.0% | -51.9% | -34.3% | -12.0% |
| Net Profit Margin | - | -2,953.9% | -457.0% | -463.9% | -338.3% | -170.4% | -42.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai MicuRx Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 0.28%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.88M | 0.01 | - |
| 2024 | CNY 6.54M | 0.01 | - |
| 2023 | CNY 4.60M | 0.01 | - |
| 2022 | CNY 3.30M | 0.01 | - |
| 2021 | CNY 697K | 0.00 | - |
| 2020 | CNY 2.43M | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai MicuRx Pharmaceutical Co. Ltd. A
- Insiders 41.48%
- Institutions 2.74%
- Public & others 55.79%
- Shares outstanding 656M
- Free float 516M
Shanghai MicuRx Pharmaceutical Co. Ltd. A company profile
- Company name
- Shanghai MicuRx Pharmaceutical Co. Ltd. A
- Ticker
- 688373.SHG
- ISIN
- CNE100005PX4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 166
- Fiscal year end
- December
- Address
- 53, Edison Road, Shanghai, China
- Phone
- 86 21 5090 0550
- Website
- micurxchina.com
About Shanghai MicuRx Pharmaceutical Co. Ltd. A
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.
Shanghai MicuRx Pharmaceutical Co. Ltd. A management
9- Dr. Yuan Zhengyu Ph.D.CEO & Chairman · born 1955
- Mr. Xinghai WangDeputy GM, CTO & Director · born 1981
- Mr. Liang LuChairman of the Supervisory Board, Director of Quality & Compliance Dept. & Dep. GM of Ops. Mgmt. · born 1983
- Ms. Hong YuanDeputy GM & Chief Clinical Officer · born 1977
- Mr. Youyin XuDeputy GM & Head of Commercial Operations · born 1968
- Ms. Anna NieBoard Secretary · born 1993
- Ms. Cui GuoFinancial Controller & Head of Accounting Department
- Mr. Liu JingianHead of Corporate Chemistry · born 1986
- Ms. Wang WenHead of Biological Department · born 1962